Latest Production News

Sarytogan Graphite Limited has upgraded its Mineral Resource Estimate to include 5.4 million tonnes of Measured graphite, underpinning a multi-decade mine life in Kazakhstan. This milestone supports the ongoing Definitive Feasibility Study due mid-2026.

Australian Clinical Labs reported a modest revenue dip but achieved growth in earnings and margins in 1H26, while updating FY26 guidance and addressing wage increases mandated by the Fair Work Commission.

Ansell Limited reported a robust 61.5% surge in net profit for the first half of FY26, driven by operational efficiencies and strategic acquisitions, while announcing a planned CEO transition.

BlueScope Steel reported a robust first half of FY2026 with underlying EBIT soaring 81% to $557.5 million and announced a $3.00 per share shareholder return plan, while decisively rejecting a $30 per share takeover proposal.

The a2 Milk Company has reported robust half-year results with strong revenue and earnings growth, driven by gains in infant formula and liquid milk segments, alongside a strategic supply chain transformation. The company has upgraded its full-year outlook and announced a substantial special dividend, signalling confidence in its growth trajectory.

Neometals Ltd has resolved a longstanding legal dispute with a $1 million settlement, clearing the way to focus on advancing its Barrambie Gold Project and sustainable processing technologies.

BTC Health’s investee, BTC Cardio, has landed exclusive Australian distribution rights for Jafron Biomedical’s hemoperfusion cartridges, aiming for a 2026 market debut pending regulatory approval.

Sky Metals Limited has raised $20.5 million through a share placement to accelerate development of its flagship Tallebung Tin Project in NSW, positioning the company for near-term tin production.

BrainChip has launched its AKD2500 silicon development project, advancing its Akida™ 2.0 neuromorphic AI platform with a $2.5 million investment and prototype expected by Q3 2026.

Felix Gold Limited has confirmed significant extensions to gold mineralisation at its NW Array prospect in Alaska's Treasure Creek, with high-grade assay results and broad gold halos around antimony veins. The mineralised system remains open for further expansion, supporting the company's dual-commodity strategy.

AVITA Medical reported a mixed fourth quarter with revenue pressures easing and full-year growth, underpinned by a new $60 million credit facility and advancing clinical trials.

AVITA Medical closed 2025 with steady revenue growth and over 80% gross margin, setting the stage for a confident revenue forecast of up to US$85 million in 2026. The company also secured a new debt facility with improved terms, underpinning its growth ambitions.